Reported December 5, 2025: Inspire Veterinary Partners Lowers Series B Preferred Stock Floor Price From $0.1879 To $0.05 Per Share And Amends Notes, Allowing ~$2.7M Redemption

As previously reported in Current Reports on Form 8-K filed by Inspire Veterinary Partners, Inc. (the "Company") on August 4, 2025 and September 15, 2025, the Company issued shares of its Series B Convertible Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock") to certain accredited investors, and established the rights, preferences and privileges of the Series B Preferred Stock pursuant to a Certificate of Designation of Series B Convertible Preferred Stock filed with the Nevada Secretary of State on July 29, 2025 (the "Certificate of Designation").

 

On December 1, 2025, pursuant to Section 32(aa) of the Certificate of Designation, the Company entered into an agreement with the Required Holders under the Certificate of Designation, to lower the Floor Price (as defined in the Certificate of Designation) from $0.1879 to $0.05 per share (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events and in accordance with the other adjustment provisions of the Certificate of Designation).

 

On December 1, 2025, the Company also entered into a waiver agreement with the Required Holders to permit a redemption of 2,027 shares of Series B Preferred Stock for approximately $2.7 million.

 

On December 4, 2025, the Company entered into an amendment to the promissory notes issued to Target Capital 1 LLC on June 10, 2025 and June 30, 2025 (the "Notes") to lower the Floor Price (as defined in the Notes) from $0.1879 to $0.05 per share (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events and in accordance with the other adjustment provisions of the Notes). The Notes also were amended to prohibit Target from converting the Notes to the extent (but only to the extent) Target or any of its affiliates would beneficially own a number of shares of the Company's Class A common stock which would exceed 4.99% of the outstanding shares of the Company.